CLCS
Cell Source, Inc. [CLCS] Stock Forecast
Buy or Sell ? Support and Resistance
What is MACD and how to read it?
How RSI can help?
RSI : 000
CLCS Stock Summary
In the News
CLCS Financial details
Company Rating
-
Market Cap
19.27M
Income
-5.61M
Revenue
0
Book val./share
-
Cash/share
-
Dividend
-
Dividend %
-
Employees
1
Optionable
No
Shortable
Yes
Earnings
23 Aug 2024
P/E
-2.93
Forward P/E
-
PEG
1.04
P/S
-
P/B
-1.02
P/C
-
P/FCF
-7.06
Quick Ratio
-
Current Ratio
0.02
Debt / Equity
-
LT Debt / Equity
-
-
-
EPS (TTM)
-0.15
EPS next Y
-
EPS next Q
-
EPS this Y
-28.57%
EPS next Y
-
EPS next 5Y
-
EPS last 5Y
-
Revenue last 5Y
-
Revenue Q/Q
-
EPS Q/Q
4.79%
-
-
-
-
SMA20
7.14%
SMA50
-9.09%
SMA100
-45.45%
Inst Own
-
Inst Trans
-
ROA
-2258%
ROE
39%
ROC
0.27%
Gross Margin
-
Oper. Margin
-
Profit Margin
-
Payout
-21%
Shs Outstand
-
Shs Float
-
-
-
-
-
Target Price
-
52W Range
3.0E-4-0.74
52W High
-
52W Low
-
RSI
51.49
Rel Volume
3.42
Avg Volume
11.22K
Volume
38.4K
Perf Week
6.67%
Perf Month
-8.68%
Perf Quarter
-28.89%
Perf Half Y
16.15%
-
-
-
-
Beta
-150.905
-
-
Volatility
0.01%, 0.03%
Prev Close
16.36%
Price
0.32
Change
23.08%
Company Profile
- Volume Average 11.22K
- Market Capitalization 19.27M
- Employee 1
- CEO Mr. Itamar Shimrat
- Headquarters New York,NY,US
- IPO Date 2014-05-01
-
Website
https://www.cell-source.com 
Cell Source, Inc., a biotechnology company, develops cell therapy treatments based on the management of immune tolerance. The company's lead product is the Veto Cell immune system management technology, which is an immune tolerance biotechnology that enables the selective blocking of immune responses. Its Veto Cell technology is used in various applications, including treatment of lymphoma, leukemia, and multiple myeloma through facilitation of the stem cell transplantation acceptance, as well as treatment of end stage kidney disease and other non-malignant organ diseases, and various cancers and non-malignant diseases. Cell Source, Inc. was founded in 2012 and is headquartered in New York, New York.
